Genmab News

To comply with applicable regulation in Denmark, product-related media releases are removed from our website within three weeks of publication. They are available upon request. Please contact us here.

Oct 19, 2021 at 12:30 PM CEST Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021	Download
Oct 15, 2021 at 7:46 PM CEST Genmab Announces that Janssen has Received Positive CHMP Opinion for RYBREVANT® (amivantamab) for Patients with Advanced Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations, After Failure of Platinum-based Therapy
Oct 15, 2021 at 3:01 PM CEST Genmab A/S has published its Articles of Association	Download
Oct 7, 2021 at 8:56 PM CEST Grant of Restricted Stock Units and Warrants to Employees in Genmab	Download
Oct 1, 2021 at 2:00 PM CEST Genmab Announces Abstracts Evaluating Investigational Solid Tumor Therapies to be Presented at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021)	Download
Sep 22, 2021 at 1:43 PM CEST Genmab A/S has published its Articles of Association	Download
Sep 21, 2021 at 8:23 PM CEST Capital Increase in Genmab as a Result of Employee Warrant Exercise	Download
Sep 20, 2021 at 11:00 PM CEST Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer	Download
Aug 27, 2021 at 10:42 AM CEST Genmab to Present at Morgan Stanley 19th Annual Global Healthcare Conference	Download
Aug 18, 2021 at 6:14 PM CEST Genmab A/S has published its Articles of Association	Download
Aug 17, 2021 at 8:52 PM CEST Capital Increase in Genmab as a Result of Employee Warrant Exercise	Download
Aug 11, 2021 at 5:02 PM CEST Genmab Announces Financial Results for the First Half of 2021	Download
Jul 21, 2021 at 6:58 PM CEST Major Shareholder Announcement	Download
Jul 21, 2021 at 12:32 PM CEST Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2021	Download
Jul 7, 2021 at 1:06 PM CEST Genmab A/S has published its Articles of Association	Download
Jul 6, 2021 at 8:05 PM CEST Capital Increase in Genmab as a Result of Employee Warrant Exercise	Download
Jul 1, 2021 at 1:55 PM CEST Genmab A/S has published its Articles of Association	Download
Jul 1, 2021 at 9:42 AM CEST Completion of share buy-back program	Download Download
Jun 28, 2021 at 9:30 AM CEST Transactions in connection with share buy-back program	Download Download
Jun 22, 2021 at 10:17 PM CEST Grant of Restricted Stock Units and Warrants to Employees in Genmab	Download
Jun 22, 2021 at 4:12 PM CEST Genmab Announces that Janssen has Received European Marketing Authorizations for DARZALEX® (daratumumab) Subcutaneous Formulation, Including for the Treatment of Patients with Newly Diagnosed Light-chain (AL) Amyloidosis	Download
Jun 21, 2021 at 9:47 AM CEST Transactions in connection with share buy-back program	Download Download
Jun 16, 2021 at 1:13 AM CEST Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons	Download
Jun 14, 2021 at 9:58 AM CEST Transactions in connection with share buy-back program	Download Download
Jun 10, 2021 at 3:54 PM CEST Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons	Download

NEWS & EVENTS

Through timely company announcements, media releases, events and presentations, Genmab discloses and informs all our stakeholders of key events throughout the year.

Genmab News

Genmab News

Who we are

Turning insights into medicine

Innovation for the future

Genmab A/S

Genmab B.V.

Genmab US, Inc.

Genmab K.K.

You are now leaving Genmab.com to go to our collaborator’s website. If you continue, we encourage you to read the website’s privacy and cookie policy.